B.S.: The STEM Podcast

SOC 204: Media or Medicine - GLP-1s

With groundbreaking medical advancements and the the rise of fatphobia and intolerance, GLP-1s feel like the awkward elephant in the room. This infamous medication has bounced around Super Bowl commercials and social media advertisements, leaving a trail of hot takes and misinformation. Today, Ilyana and Gold explain the real function of the drug and discuss the historical background of weight marginalization and the social implications of GLP-1 medications. Get settled, it’s a long one. Listen To Us Anywhere: YouTube: https://www.youtube.com/channel/UC5Bf6Gk-SuKnWK0zI0i3M3Q [https://www.youtube.com/channel/UC5Bf6Gk-SuKnWK0zI0i3M3Q] Contact Us: bspodcast79@gmail.com [bspodcast79@gmail.com] Music: William Pleasant Design: Matheus Lago Required Reading: GLP-1 Agonists: What They Are, How They Work & Side Effects [https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists] GLP-1 and health: Beyond weight loss in the Ozempic era [https://health.ucdavis.edu/news/health-wellness/glp-1-and-health-beyond-weight-loss-in-the-ozempic-era/2025/11] How does Ozempic work? Understanding GLP-1s for diabetes, weight loss, and beyond - Harvard Health [https://www.health.harvard.edu/staying-healthy/how-does-ozempic-work-understanding-glp-1s-for-diabetes-weight-loss-and-beyond] New GLP-1 weight-loss drugs are coming—and they’re stronger than Wegovy and Zepbound | Scientific American [https://www.scientificamerican.com/article/new-glp-1-weight-loss-drugs-are-coming-and-theyre-stronger-than-wegovy-zepbound/] GLP-1 obesity drugs and eating disorders are not well understood yet : NPR [https://www.npr.org/2026/02/04/nx-s1-5677633/glp-1-obesity-wegovy-zepbound-eating-disorders-anorexia-bulimia] Comparing the Impact of GLP-1 Agonists vs. Lifestyle Interventions and Weight Controllability Information on Stigma and Weight-Related Cognitions | International Journal of Behavioral Medicine | Springer Nature Link [https://link.springer.com/article/10.1007/s12529-025-10353-2] WHO issues global guideline on the use of GLP-1 medicines in treating obesity [https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity] Addressing weight bias in medicine - Harvard Health [https://www.health.harvard.edu/blog/addressing-weight-bias-in-medicine-2019040316319] Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management [https://pubmed.ncbi.nlm.nih.gov/41177120/] GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists [https://pubmed.ncbi.nlm.nih.gov/32459834/] GLP-1 diabetes and weight-loss drug side effects: "Ozempic face" and more [https://www.health.harvard.edu/staying-healthy/glp-1-diabetes-and-weight-loss-drug-side-effects-ozempic-face-and-more] KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs [https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/] Where does fat phobia come from? [https://www.universityofcalifornia.edu/news/where-does-fat-phobia-come] The History and Faults of the Body Mass Index and Where to Look Next: A Literature Review [https://pubmed.ncbi.nlm.nih.gov/38050494/] The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity [https://www.sciencedirect.com/science/article/pii/S2666634025002326] Dangers and Opportunities of Direct-to-Consumer Advertising [https://pmc.ncbi.nlm.nih.gov/articles/PMC5910355/] Impact of weight bias and stigma on quality of care and outcomes for patients with obesity [https://pmc.ncbi.nlm.nih.gov/articles/PMC4381543/] Opinion Pieces: I’ve Had 2 Weight-Loss Surgeries And Now I’m On Wegovy. None Of It Made Me Any Healthier. | HuffPost HuffPost Personal [https://www.huffpost.com/entry/weight-loss-surgery-glp1s-fatphobia-health_n_68c45aece4b0b3dca95eb648] #stem #glp1 #fatphobia #research #medicine

28. feb. 2026 - 1 h 12 min